The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
L | Antineoplastic and immunomodulating agents | |
2
|
L01 | Antineoplastic agents | |
3
|
L01E | Protein kinase inhibitors | |
4
|
L01EM | Phosphatidylinositol-3-kinase (Pi3K) inhibitors | |
5
|
L01EM04 |
| Active Ingredient |
|---|
|
Duvelisib is a dual inhibitor of phosphatidylinositol 3-kinase p110δ (PI3K-δ) and PI3K-γ. PI3K-δ inhibition directly reduces proliferation and survival of malignant B-cell lines and primary CLL tumour cells, while PI3K-γ inhibition reduces the activity of CD4+ T cells and macrophages in the tumor microenvironment to support the malignant B cells. |
| Document | Type | Information Source | |
|---|---|---|---|
| COPIKTRA Capsule | MPI, US: SPL/PLR | FDA, National Drug Code (US) | |
| COPIKTRA Hard capsule | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.